The first report of the Mashelkar Committee on patent issues was accused of plagiarism and the committee was asked by the government to rexamine its recommendations. The second report of this committee poses a different set of problems. This article argues that the revised recommendations are not warranted by the TRIPs agreement of the World Trade Organisation, that they are not supported by the weight of academic opinion and that the conclusions do not rest on any reasonable assessment of national interest in pharmaceutical policy.
Access the article here.
Cite:
Sudhir Krishnaswamy, Mashelkar Report on IP Rights Version II: Wrong Again (EPW, 26th December 2009)